Stock APPH APONTIS PHARMA AG
Add to a list
To use this feature you must be a member
Log inSign up

News Apontis Pharma AG

Equities

APPH

DE000A3CMGM5

Market Closed - Xetra
Other stock markets
 09:06:18 29/05/2024 pm IST 		5-day change 1st Jan Change
8.18 EUR -2.39% Intraday chart for Apontis Pharma AG -9.91% +72.21%
05/04 Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications MT
28/03 Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
DD: APONTIS PHARMA AG: Thomas Milz, buy
EQ
DD: APONTIS PHARMA AG: be executive GmbH, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy
EQ
Apontis Pharma : Earnings Call Q1/24 Presentation
PU
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
EQ
Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications
MT
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQ
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQ
Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Apontis Pharma AG, 2023 Earnings Call, Mar 28, 2024
APONTIS PHARMA expects profitable growth again in 2024
EQ
Apontis Pharma : Earnings Call 2023 Presentation
PU
Transcript : Apontis Pharma AG - Special Call
APONTIS PHARMA successfully completes performance and efficiency improvement program
EQ
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
EQ
Apontis Pharma Provides Earnings Guidance for the Full Year 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APPH Stock
  4. News Apontis Pharma AG